Clinical Trials Browser

Interventional × Has announcements × cabozantinib × Clear all

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase 3 Active not recruiting

187 enrolled 13 charts 1 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01908426 2021-05-06

CELESTIAL

Phase 3 Completed

707 enrolled 20 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 1 FDA

Carcinoma, Renal Cell